646 results on '"Champlin, R. E."'
Search Results
2. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients
3. PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies
4. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes
5. P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
6. P1344: METHODOLOGY OF AN INTERNATIONAL MULTI-CENTER RETROSPECTIVE REVIEW OF TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (TA-TMA) BY THE TA-TMA WORKING GROUP
7. HLA-mismatched bone marrow transplantation in severe aplastic anemia
8. Pushing the envelope—nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation
9. Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma
10. Comparison of outcomes at two institutions of patients with ALL receiving ex vivo T-cell-depleted or unmodified allografts
11. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation
12. Complement component C3 mediates Th1/Th17 polarization in human T-cell activation and cutaneous GVHD
13. Symptomatic BK Virus Infection Is Associated With Kidney Function Decline and Poor Overall Survival in Allogeneic Hematopoietic Stem Cell Recipients
14. Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?
15. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes
16. Targeting Brutonʼs Tyrosine Kinase With Ibrutinib in B-Cell Malignancies
17. Vaccination guidelines after hematopoietic stem cell transplantation: practitionersʼ knowledge, attitudes, and gap between guidelines and clinical practice
18. Adenoviral infections in adult allogeneic hematopoietic SCT recipients: a single center experience
19. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia
20. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL
21. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR
22. Prognostic value of response after upfront therapy for acute GVHD
23. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor
24. Phase II trial of high-dose topotecan, melphalan and CY with autologous stem cell support for multiple myeloma
25. CD3+ and/or CD14+ depletion from cord blood mononuclear cells before ex vivo expansion culture improves total nucleated cell and CD34+ cell yields
26. Utility of early versus late fiberoptic bronchoscopy in the evaluation of new pulmonary infiltrates following hematopoietic stem cell transplantation
27. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT
28. Infections in non-myeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention
29. SUCCESSFUL TREATMENT FOR SECONDARY AML AND MDS FOLLOWING MYELOABLATIVE HEMATOPOETIC STEM CELL TRANSPLANTATION FOR CHILDREN, ADOLESCENTS AND YOUNG ADULTS: PH-P577
30. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer
31. Leukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML
32. Allogeneic hematopoietic cell transplantation for metastatic breast cancer
33. Phase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome
34. Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation
35. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation
36. Risk factors associated with late cytomegalovirus reactivation after allogeneic stem cell transplantation for hematological malignancies
37. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
38. High-dose caspofungin combination antifungal therapy in patients with hematologic malignancies and hematopoietic stem cell transplantation
39. Phase II study of unrelated cord blood transplantation for adults with high-risk hematologic malignancies
40. Allogeneic hematopoietic stem cell transplantation after rituximab-containing myeloablative preparative regimen for acute lymphoblastic leukemia
41. High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy
42. A novel triple purge strategy for eliminating chronic myelogenous leukemia (CML) cells from autografts
43. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia
44. Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
45. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant
46. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response
47. Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?
48. Comparison of 100-day mortality rates associated with i.v. busulfan and cyclophosphamide vs other preparative regimens in allogeneic bone marrow transplantation for chronic myelogenous leukemia: Bayesian sensitivity analyses of confounded treatment and center effects
49. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation
50. Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.